Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions

Sex: All

Ages: 19 Years – 75 Years

Enrollment: 236

Sponsor: Soonchunhyang University Hospital

Summary

This is the prospective observational study to explore whether the SpyGlass DS II system could be used to screen early-stage neoplastic bile duct lesions in selected patients.

Eligibility Criteria

Inclusion Criteria:Aged > 18 yearsPatients with risk factors for CCA (viral hepatitis, parasitic infection, choledochal cyst, primary sclerosing cholangitis, biliary stones, and toxins)Patients who undergo ERCP for confirmation of CBD clearanceDilated common bile duct (> 10 mm)Previous sphincteroplasty, such as major endoscopic sphincterotomy and/or endoscopic papillary balloon dilatationExclusion Criteria:Presence of biliary tract cancerPresence of distal CBD strictureBleeding tendency (INR>1.5 or platelets <50000 mm3)Contraindications of ERCP

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05600803). StuddyBuddy aggregates publicly available trial information.